Castellano | Euskara | Français | English
DTB: Vol 24, No 3
Share it
The EMPA-REG OUTCOME trial (empagliflozin). A critical appraisal. The power of truth, the truth of power
There is no solid evidence supporting the claims of superiority of empagliflozin over placebo for the prevention of macrovascular complications in diabetic patients with cardiovascular disease. The limitations of the EMPA-REG OUTCOME trial should be appropriately addressed before the drug’s indications are extended. Also, a confirmatory trial should be conducted to verify the results of the first study.
Author:
- Luis Carlos Saiz. Pharmacist. Pharmacotherapy Research Coordinator Navarre Health Service. Spain
